UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy

JNCI : Journal of the National Cancer Institute, 2012-03, Vol.104 (6), p.476-487

2012

Volltextzugriff (PDF)

MicroRNA 132 Regulates Nutritional Stress-Induced Chemokine Production through Repression of SirT1

Molecular endocrinology (Baltimore, Md.), 2009-11, Vol.23 (11), p.1876-1884

2009

Volltextzugriff (PDF)

Adipose Mitochondrial Biogenesis Is Suppressed in db/db and High-Fat Diet–Fed Mice and Improved by Rosiglitazone

Diabetes (New York, N.Y.), 2007-07, Vol.56 (7), p.1751-1760

2007

Volltextzugriff (PDF)

CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy

Journal for immunotherapy of cancer, 2020-10, Vol.8 (2), p.e000847

2020

Volltextzugriff (PDF)

The Orphan G Protein-coupled Receptors GPR41 and GPR43 Are Activated by Propionate and Other Short Chain Carboxylic Acids

The Journal of biological chemistry, 2003-03, Vol.278 (13), p.11312-11319

2003

Volltextzugriff (PDF)

Activation of Peroxisome Proliferator–Activated Receptor (PPAR)δ Promotes Reversal of Multiple Metabolic Abnormalities, Reduces Oxidative Stress, and Increases Fatty Acid Oxidation in Moderately Obese Men

Diabetes (New York, N.Y.), 2008-02, Vol.57 (2), p.332-339

2008

Volltextzugriff (PDF)

The Orphan G Protein-coupled Receptor GPR40 Is Activated by Medium and Long Chain Fatty Acids

The Journal of biological chemistry, 2003-03, Vol.278 (13), p.11303-11311

2003

Volltextzugriff (PDF)

CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPC

Molecular cancer research, 2017-06, Vol.15 (6), p.660-669

2017

Volltextzugriff (PDF)

CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation

Cancer discovery, 2018-02, Vol.8 (2), p.216-233

2018

Volltextzugriff (PDF)

Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression

Molecular cancer therapeutics, 2016-05, Vol.15 (5), p.783-793

2016

Volltextzugriff (PDF)

Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion

Science translational medicine, 2017-04, Vol.9 (387)

2017

Volltextzugriff (PDF)

G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer

Breast cancer research and treatment, 2020-04, Vol.180 (3), p.635-646

2020

Volltextzugriff (PDF)

Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors

Oncotarget, 2017-06, Vol.8 (26), p.42343-42358

2017

Volltextzugriff (PDF)

Rosiglitazone Induces Mitochondrial Biogenesis in Differentiated Murine 3T3-L1 and C3H/10T1/2 Adipocytes

PPAR Research, 2011-01, Vol.2011 (2011), p.27-37

2011

Volltextzugriff (PDF)

Rosiglitazone induces mitochondrial biogenesis in mouse brain

Journal of Alzheimer's disease, 2007-03, Vol.11 (1), p.45-51

2007

Volltextzugriff (PDF)

Abstract 4414: Inhibition of CDK2 overcomes primary and acquired resistance to CDK4/6 inhibitors

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.4414-4414

2019

Volltextzugriff (PDF)

Recovery and Expression of Messenger RNA from Postmortem Human Brain Tissue

Modern pathology, 2001-11, Vol.14 (11), p.1157-1161

2001

Volltextzugriff (PDF)

Abstract 4415: CDK4/6 inhibition with lerociclib (G1T38) delays acquired resistance to targeted therapies in preclinical models of non-small cell lung cancer

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.4415-4415

2019

Volltextzugriff (PDF)

Abstract 4426: Selective inhibition of CDK9 induces apoptosis of TNBC cells independent of Rb status

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.4426-4426

2019

Volltextzugriff (PDF)

Abstract 1752: Transient exposure of trilaciclib, a CDK4/6 inhibitor, modulates gene expression in tumor immune infiltrates to promote a pro-inflammatory tumor microenvironment

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.1752-1752

2018

Volltextzugriff (PDF)

Abstract 1522: The CDK4/6 inhibitor G1T38 enhances response to targeted therapies in preclinical models of non-small cell lung cancer

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.1522-1522

2018

Volltextzugriff (PDF)

Abstract 5628: Trilaciclib (G1T28), a CDK4/6 inhibitor, enhances the efficacy of combination chemotherapy and immune checkpoint inhibitor treatment in preclinical models

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.5628-5628

2017

Volltextzugriff (PDF)

Abstract 2824: G1T38, a novel, oral, potent and selective CDK4/6 inhibitor for the treatment of Rb competent tumors

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.2824-2824

2016

Volltextzugriff (PDF)

Abstract 5994: INX-315, a potent and selective CDK2 inhibitor, demonstrates robust antitumor activity in CCNE1 -amplified cancers

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.5994-5994

2023

Volltextzugriff (PDF)

Serum adiponectin as a biomarker for in vivo PPARgamma activation and PPARgamma agonist-induced efficacy on insulin sensitization/lipid lowering in rats

BMC pharmacology, 2004-10, Vol.4 (1), p.23-23, Article 23

2004

Volltextzugriff (PDF)

1 – 25 von 61

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(55)
Mit Volltextzugriff
(55)

Publikationsform

Artikel
(61)

Sprache

Englisch
(61)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy

MicroRNA 132 Regulates Nutritional Stress-Induced Chemokine Production through Repression of SirT1

Adipose Mitochondrial Biogenesis Is Suppressed in db/db and High-Fat Diet–Fed Mice and Improved by Rosiglitazone

CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy

The Orphan G Protein-coupled Receptors GPR41 and GPR43 Are Activated by Propionate and Other Short Chain Carboxylic Acids

Activation of Peroxisome Proliferator–Activated Receptor (PPAR)δ Promotes Reversal of Multiple Metabolic Abnormalities, Reduces Oxidative Stress, and Increases Fatty Acid Oxidation in Moderately Obese Men

The Orphan G Protein-coupled Receptor GPR40 Is Activated by Medium and Long Chain Fatty Acids

CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPC

CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation

Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression

Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion

G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer

Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors

Rosiglitazone Induces Mitochondrial Biogenesis in Differentiated Murine 3T3-L1 and C3H/10T1/2 Adipocytes

Rosiglitazone induces mitochondrial biogenesis in mouse brain

Abstract 4414: Inhibition of CDK2 overcomes primary and acquired resistance to CDK4/6 inhibitors

Recovery and Expression of Messenger RNA from Postmortem Human Brain Tissue

Abstract 4415: CDK4/6 inhibition with lerociclib (G1T38) delays acquired resistance to targeted therapies in preclinical models of non-small cell lung cancer

Abstract 4426: Selective inhibition of CDK9 induces apoptosis of TNBC cells independent of Rb status

Abstract 1752: Transient exposure of trilaciclib, a CDK4/6 inhibitor, modulates gene expression in tumor immune infiltrates to promote a pro-inflammatory tumor microenvironment

Abstract 1522: The CDK4/6 inhibitor G1T38 enhances response to targeted therapies in preclinical models of non-small cell lung cancer

Abstract 5628: Trilaciclib (G1T28), a CDK4/6 inhibitor, enhances the efficacy of combination chemotherapy and immune checkpoint inhibitor treatment in preclinical models

Abstract 2824: G1T38, a novel, oral, potent and selective CDK4/6 inhibitor for the treatment of Rb competent tumors

Abstract 5994: INX-315, a potent and selective CDK2 inhibitor, demonstrates robust antitumor activity in CCNE1 -amplified cancers

Serum adiponectin as a biomarker for in vivo PPARgamma activation and PPARgamma agonist-induced efficacy on insulin sensitization/lipid lowering in rats

Suchergebnisse filtern